Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without C9orf72 Mutation
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To determine whether the neuropsychological profiles of patients with amyotrophic lateral sclerosis (ALS) with (ALSC9+) and without (ALSC9−) C9orf72 expansion are different, we administered a battery of neuropsychological tests to 741 patients with ALS (68 ALSC9+ and 673 ALSC9−) and 129 controls.
Methods The study population includes 741 patients with ALS who were consecutively diagnosed at the Turin ALS expert center in the 2010–2018 period and who underwent both cognitive/behavioral and genetic testing. Patients' neuropsychological patterns were compared (1) at the same degree of cognitive and behavioral deficit according to the revised ALS–Frontotemporal Dementia Consensus Criteria and (2) at the same level of motor impairment according to the King staging system.
Results Despite being about 7 years younger, ALSC9+ patients had significantly lower scores in tests exploring executive function and verbal memory both when classified as cognitively normal and when diagnosed in the intermediate cognitive categories. Considering the clinical perspective, ALSC9+ patients showed significantly lower scores compared to ALSC9− patients at King stage 1 and 3 in almost all the examined neuropsychological domains; at King stage 2, ALSC9+ patients were more severely affected only in the verbal memory domain. Behavioral function was comparably impaired in the 2 cohorts.
Conclusions ALSC9+ patients show a different neuropsychological profile compared to ALSC9− patients, being more impaired in executive functions and verbal memory domains at all King stages. Verbal memory emerged as a particularly vulnerable function in ALSC9+, with worse performances even when patients were still classified as cognitively normal.
Glossary
- ALS=
- amyotrophic lateral sclerosis;
- ALS-CN=
- amyotrophic lateral sclerosis, cognitively normal;
- ALSbi=
- amyotrophic lateral sclerosis with behavioral impairment;
- ALScbi=
- amyotrophic lateral sclerosis with cognitive and behavioral impairment;
- ALSci=
- amyotrophic lateral sclerosis with cognitive impairment;
- ALSFRS-R=
- ALS Functional Rating Scale–revised;
- BSRT=
- Babcock Story Recall Test;
- CAT=
- category fluency test;
- DR=
- delayed recall;
- FAB=
- Frontal Assessment Battery;
- FrSBe=
- Frontal Systems Behaviour Scale;
- FTD=
- frontotemporal dementia;
- IR=
- immediate recall;
- MCI=
- mild cognitive impairment;
- MMSE=
- Mini-Mental State Examination;
- NIV=
- noninvasive ventilation;
- RAVLT=
- Rey Auditory Verbal Learning Test;
- TMT=
- Trail-Making Test
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received April 19, 2020.
- Accepted in final form August 21, 2020.
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sharon Poisson and Dr. Tiffany Brown
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Multiparametric MRI study of ALS stratified for the C9orf72 genotypePeter Bede, Arun L.W. Bokde, Susan Byrne et al.Neurology, June 14, 2013 -
Article
Basal ganglia pathology in ALS is associated with neuropsychological deficitsJudith Machts, Kristian Loewe, Joern Kaufmann et al.Neurology, September 18, 2015 -
Article
Cognitive impairment across ALS clinical stages in a population-based cohortAdriano Chiò, Cristina Moglia, Antonio Canosa et al.Neurology, August 13, 2019 -
Articles
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseasesWouter van Rheenen, Marka van Blitterswijk, Mark H.B. Huisman et al.Neurology, July 25, 2012